Hosted on MSN
Acurx signals ongoing cost controls and new trial funding avenues while advancing ibezapolstat clinical program
Luci explained that efforts to secure partnerships, including with government agencies, are ongoing and "will certainly slip into 2026, given the dynamics that are going on in Washington," but ...
Q1 2025 Management View David Luci, President and CEO, highlighted several significant developments, including the closing of a $2.5 million registered direct offering and the receipt of positive ...
Expanding clinical trial infrastructure in community oncology is vital for equitable access to novel therapies, especially in underserved populations. Site management organizations can aid in scaling ...
The Europe clinical trials market offers growth opportunities through a strong regulatory framework and rising R&D ...
HOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the "Company”), a healthcare company ...
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in ...
VYNE Therapeutics Inc. has provided an update on its clinical program for VYN202, an oral small molecule BET inhibitor aimed at treating moderate-to-severe plaque psoriasis. Following a clinical hold ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results